SRL172 + mitomycin + vinblastine + cisplatin

SRL172 is a heat-killed preparation of Mycobacterium vaccae used as an immunotherapeutic agent in cancer treatment. Mitomycin, vinblastine, and cisplatin are chemotherapeutic agents commonly combined in regimens such as MVP (mitomycin-vinblastine-cisplatin or carboplatin). The regimen "SRL172 + mitomycin + vinblastine + cisplatin" has been studied in clinical trials for advanced non-small cell lung cancer (NSCLC) and mesothelioma. The mechanism of action involves both immune stimulation by SRL172 and cytotoxic effects from the chemotherapy agents[1][2]. Clinical studies suggest that adding SRL172 to chemotherapy may improve quality of life and possibly response rates without significantly affecting overall survival[2].